J&J’s Canagliflozin Positive Phase III Data In The Limelight At ADA
This article was originally published in The Pink Sheet Daily
Executive Summary
Five Phase III trials presented at ADA show J&J’s canagliflozin improves glycemic control over existing treatments and could offer a weight loss benefit to diabetes patients; they are part of a nine-study package that J&J submitted to FDA for approval May 31.
You may also be interested in...
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.
Conflict of Interest Reform: Greatest Impact May Be Committee Vacancy Rate
FDA user fee reauthorization eliminates limits on waivers, which may ease the burden on FDA to fill open seats on its advisory committees. Vacancy rates have been as high as 24% in FY 2012.